指南与共识炎症性肠病消化道肿瘤与早癌

粪菌移植科学前沿:亚太胃肠病学会与消化内镜学会联合文件

Scientific frontiers in faecal microbiota transplantation: joint document of Asia-Pacific Association of Gastroenterology (APAGE) and Asia-Pacific Society for Digestive Endoscopy (APSDE).
指南 / 共识 · Gut · 2019-10-14

该联合文件由亚太胃肠病学会(APAGE)与亚太消化内镜学会(APSDE)组织16位专家,通过系统检索和圆桌讨论形成共识。文件围绕供受体微生物参数、菌群评估方法、关键物种与预测因素、受体特征与抗生素预处理影响、FMT制剂与递送新进展五个问题展开,指出FMT结局差异与供受体微生物组成及功能差异相关,FMT需优化后方可评估其治疗潜力。

要点

  • FMT结局差异与受体菌群组成和功能差异及供受体生理遗传因素相关
  • 供体肠道菌群分类组成可能影响FMT对复发性艰难梭菌感染和UC的疗效
  • FMT非一刀切方案,需研究不同疾病中起特定作用的微生物组分

核心结论

  • FMT需先优化才能评估其针对不同疾病的治疗前景,本摘要将指导FMT科学与实践的未来方向与优先事项。

研究设计与样本

  • 系统检索FMT文献并进行批判性评价,召开为期一天的圆桌讨论,由16位国际专家就FMT研究关键问题达成专家共识。

主要发现

  • 专家讨论五个问题:供受体微生物参数在FMT中的作用;评估菌群改变的方法;关键物种概念与FMT微生物预测因素;受体特征与抗生素预处理对FMT定植和维持的影响;FMT制剂与递送的新进展。
  • 专家组认为FMT结局差异与受体菌群的组成和功能差异有关,也可能与供体相关及受体相关的生理和遗传因素有关。
  • 供体肠道菌群的分类组成可能影响FMT对复发性艰难梭菌感染和溃疡性结肠炎(UC)的疗效。
  • FMT不仅改变细菌组成,还建立肠道真菌、病毒和细菌之间的跨界平衡以促进微生物稳态恢复。
  • FMT并非一刀切方案,需研究识别对不同疾病患者具有特定作用的微生物组分。

临床怎么用

  • 临床应认识到FMT结局受供受体菌群组成与功能差异影响,不宜将FMT视为统一方案。
  • 供体肠道菌群分类组成可能影响复发性艰难梭菌感染和UC的FMT疗效,选择供体时需考虑。
  • FMT可改变细菌组成并建立真菌、病毒与细菌的跨界平衡,评估疗效时可关注微生物稳态恢复。

局限性

  • FMT发挥获益的潜在微生物基础、治疗结局预测因素和活性成分仍未知。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The underlying microbial basis, predictors of therapeutic outcome and active constituent(s) of faecal microbiota transplantation (FMT) mediating benefit remain unknown. An international panel of experts presented key elements that will shape forthcoming FMT research and practice. DESIGN: Systematic search was performed, FMT literature was critically appraised and a 1-day round-table discussion was conducted to derive expert consensus on key issues in FMT research. RESULTS: 16 experts convened and discussed five questions regarding (1) the role of donor and recipient microbial (bacteria, viruses, fungi) parameters in FMT; (2) methods to assess microbiota alterations; (3) concept of keystone species and microbial predictors of FMT, (4) influence of recipient profile and antibiotics pretreatment on FMT engraftment and maintenance and (5) new developments in FMT formulations and delivery. The panel considered that variable outcomes of FMT relate to compositional and functional differences in recipient's microbiota, and likely donor-associated and recipient-associated physiological and genetic factors. Taxonomic composition of donor intestinal microbiota may influence the efficacy of FMT in recurrent Clostridioides difficile infections and UC. FMT not only alters bacteria composition but also establishes trans-kingdom equilibrium between gut fungi, viruses and bacteria to promote the recovery of microbial homeostasis. FMT is not a one size fits all and studies are required to identify microbial components that have specific effects in patients with different diseases. CONCLUSION: FMT requires optimisation before their therapeutic promise can be evaluated for different diseases. This summary will guide future directions and priorities in advancement of the science and practice of FMT.

来源:Gut,查看原文。版权归原作者所有。

引用

  1. Ng SC, Kamm MA, Yeoh YK, et al. Scientific frontiers in faecal microbiota transplantation: joint document of Asia-Pacific Association of Gastroenterology (APAGE) and Asia-Pacific Society for Digestive Endoscopy (APSDE). Gut. 2019. PMID: 31611298. doi:10.1136/gutjnl-2019-319407

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。